Please Wait.....
Report
Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others), By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others), By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched), By Offering (Products, Services), By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic and Research Institutes), By Region and Competition, 2020-2030F
Market Report I 2025-04-11 I 187 Pages I TechSci Research
Global Next-Generation Breast Cancer Diagnostic and Screening Market was valued at USD 4.65 Billion in 2024 and is expected to reach USD 8.53 Billion in the forecast period with a CAGR of 10.61% through 2030. Next-generation breast cancer diagnostic and screening methods refer to advanced and innovative approaches to detecting and diagnosing breast cancer. These methods incorporate cutting-edge technologies, molecular insights, and personalized approaches to improve the accuracy and effectiveness of breast cancer detection, diagnosis, and risk assessment. Next-generation methods enable the molecular subtyping of breast cancer based on specific genetic markers. This subtyping provides insights into the tumor's behavior and helps determine the most appropriate treatment strategy. Common subtypes include hormone receptor-positive, HER2-positive, and triple-negative breast cancer. The increasing incidence of breast cancer worldwide has been a significant driver. As breast cancer rates continue to rise, the demand for advanced diagnostic and screening methods to detect the disease at an early stage has also increased.
Ongoing technological advancements in breast imaging, genetic testing, and molecular diagnostics have improved the accuracy and early detection of breast cancer, driving demand for these technologies. The shift toward personalized medicine has led to an increased demand for diagnostic tests that provide individualized information about a patient's breast cancer subtype and genetic profile. This information guides treatment decisions. Breast cancer awareness campaigns and initiatives promoting early detection have encouraged more women to undergo regular breast cancer screening, contributing to market growth.
Key Market Drivers
Advancements in Technology
Digital mammography has largely supplanted traditional film mammography, offering enhanced image quality, streamlined storage and retrieval, and the capability to manipulate images for improved visualization of breast tissue. As of June 2023, the U.S. Food and Drug Administration reported that 87% of mammography facilities in the United States have adopted 3D mammography systems, also known as breast tomosynthesis, which capture multiple X-ray images from different angles to create a three-dimensional representation of the breast. This technology has been shown to reduce false positives and improve cancer detection, particularly in women with dense breast tissue.
Breast Magnetic Resonance Imaging (MRI) utilizes powerful magnets and radio waves to generate detailed images of breast tissue, proving especially useful for assessing disease extent and detecting tumors in high-risk women. Advanced ultrasound technologies, including elastography and contrast-enhanced ultrasound, offer additional insights into breast lesions, aiding in distinguishing between benign and malignant tumors. Genetic testing has advanced with next-generation sequencing, allowing simultaneous analysis of multiple genes to comprehensively assess mutations associated with breast cancer.
Key Market Challenges
Ethical and Legal Issues
As next-generation diagnostic and screening methods generate large volumes of sensitive patient data, ensuring privacy and data security becomes paramount. Ethical concerns arise regarding the storage, sharing, and protection of patient genetic and medical information. Patients must provide informed consent before undergoing genetic testing or other screening procedures. Ensuring that patients fully understand the implications of the tests, including potential psychological and medical consequences, is an ethical imperative. Concerns about genetic discrimination in employment, insurance, and other areas may deter individuals from undergoing genetic testing. Legal protections against such discrimination are essential to address these concerns. Ethical and legal questions arise about who owns the genetic and medical data generated through screening. This includes issues related to data access, sharing, and commercialization. Next-generation screening technologies must adhere to regulatory standards to ensure safety, accuracy, and efficacy. Navigating the complex regulatory landscape can be a challenge for companies and healthcare providers. Ethical issues related to healthcare equity and access arise when next-generation screening technologies are not equally available to all populations. Disparities in access can lead to unequal health outcomes.
Key Market Trends
Integration of Multi-Omics Data
Multi-omics approaches enable healthcare providers to obtain a detailed profile of breast cancer at the molecular level. This includes information on genetic mutations, gene expression patterns, protein activity, metabolite levels, and epigenetic modifications. Integration of multi-omics data allows for precise molecular subtyping of breast cancer, which helps tailor treatment strategies based on the unique characteristics of each patient's tumor. This approach enhances the effectiveness of targeted therapies and minimizes unnecessary treatments. Multi-omics data analysis can identify biomarkers associated with early-stage breast cancer and risk prediction. This aids in early detection and risk assessment, enabling healthcare providers to intervene at an earlier, more treatable stage. Multi-omics analysis identifies specific molecular targets within breast cancer cells that can be exploited for treatment. This leads to the development of targeted therapies and more effective treatment options. Multi-omics data can be used to monitor a patient's response to treatment over time. Changes in gene expression, protein activity, or metabolite levels can indicate treatment efficacy or the need for therapeutic adjustments.
Key Market Players
- Abbott Laboratories
- Agendia Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Genomics Co., Ltd.
- CENTOGENE N.V
- Danaher Corporation
- Exact Sciences Corporation
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Lucence Diagnostics Pte Ltd.
Report Scope:
In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology:
o Real-Time PCR
o Immunohistochemistry (IHC)
o Next-Generation Sequencing (NGS)
o Fluorescence In-Situ Hybridization (FISH)
o Others
- Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker:
o BRCA1/2
o ER/PR Receptors
o HER-2
o Others
- Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type:
o Luminal A
o Luminal B
o Triple Negative/Basal Like
o Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched
- Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering:
o Products
o Services
- Next-Generation Breast Cancer Diagnostic and Screening Market, By End User:
o Hospitals and Clinics
o Diagnostic Centers, and Reference Labs
o Academic and Research Institutes
- Next-Generation Breast Cancer Diagnostic and Screening Market, By region:
o North America
United States
Canada
Mexico
o Asia-Pacific
China
India
South Korea
Australia
Japan
o Europe
Germany
France
United Kingdom
Spain
Italy
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.
Available Customizations:
Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
5.2.4. By Offering (Products, Services)
5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers, and Reference Labs, Academic and Research Institutes)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Biomarker
6.2.3. By Cancer Sub-Type
6.2.4. By Offering
6.2.5. By End User
6.2.6. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Biomarker
6.3.1.2.3. By Cancer Sub-Type
6.3.1.2.4. By Offering
6.3.1.2.5. By End User
6.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Biomarker
6.3.2.2.3. By Cancer Sub-Type
6.3.2.2.4. By Offering
6.3.2.2.5. By End User
6.3.3. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Biomarker
6.3.3.2.3. By Cancer Sub-Type
6.3.3.2.4. By Offering
6.3.3.2.5. By End User
6.3.4. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Technology
6.3.4.2.2. By Biomarker
6.3.4.2.3. By Cancer Sub-Type
6.3.4.2.4. By Offering
6.3.4.2.5. By End User
6.3.5. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Technology
6.3.5.2.2. By Biomarker
6.3.5.2.3. By Cancer Sub-Type
6.3.5.2.4. By Offering
6.3.5.2.5. By End User
7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Biomarker
7.2.3. By Cancer Sub-Type
7.2.4. By Offering
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Biomarker
7.3.1.2.3. By Cancer Sub-Type
7.3.1.2.4. By Offering
7.3.1.2.5. By End User
7.3.2. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Biomarker
7.3.2.2.3. By Cancer Sub-Type
7.3.2.2.4. By Offering
7.3.2.2.5. By End User
7.3.3. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Biomarker
7.3.3.2.3. By Cancer Sub-Type
7.3.3.2.4. By Offering
7.3.3.2.5. By End User
7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Biomarker
7.3.4.2.3. By Cancer Sub-Type
7.3.4.2.4. By Offering
7.3.4.2.5. By End User
7.3.5. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Biomarker
7.3.5.2.3. By Cancer Sub-Type
7.3.5.2.4. By Offering
7.3.5.2.5. By End User
8. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Biomarker
8.2.3. By Cancer Sub-Type
8.2.4. By Offering
8.2.5. By End User
8.2.6. By Country
8.3. North America: Country Analysis
8.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Biomarker
8.3.1.2.3. By Cancer Sub-Type
8.3.1.2.4. By Offering
8.3.1.2.5. By End User
8.3.2. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Biomarker
8.3.2.2.3. By Cancer Sub-Type
8.3.2.2.4. By Offering
8.3.2.2.5. By End User
8.3.3. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Biomarker
8.3.3.2.3. By Cancer Sub-Type
8.3.3.2.4. By Offering
8.3.3.2.5. By End User
9. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Biomarker
9.2.3. By Cancer Sub-Type
9.2.4. By Offering
9.2.5. By End User
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Biomarker
9.3.1.2.3. By Cancer Sub-Type
9.3.1.2.4. By Offering
9.3.1.2.5. By End User
9.3.2. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Biomarker
9.3.2.2.3. By Cancer Sub-Type
9.3.2.2.4. By Offering
9.3.2.2.5. By End User
9.3.3. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Biomarker
9.3.3.2.3. By Cancer Sub-Type
9.3.3.2.4. By Offering
9.3.3.2.5. By End User
10. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Biomarker
10.2.3. By Cancer Sub-Type
10.2.4. By Offering
10.2.5. By End User
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Biomarker
10.3.1.2.3. By Cancer Sub-Type
10.3.1.2.4. By Offering
10.3.1.2.5. By End User
10.3.2. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Biomarker
10.3.2.2.3. By Cancer Sub-Type
10.3.2.2.4. By Offering
10.3.2.2.5. By End User
10.3.3. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Biomarker
10.3.3.2.3. By Cancer Sub-Type
10.3.3.2.4. By Offering
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis
14. Porters Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Abbott Laboratories
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Agendia Inc.
16.3. Agilent Technologies, Inc.
16.4. Bio-Rad Laboratories, Inc.
16.5. BGI Genomics Co., Ltd.
16.6. CENTOGENE N.V.
16.7. Danaher Corporation
16.8. Exact Sciences Corporation
16.9. F. Hoffmann-La Roche Ltd.
16.10. Illumina, Inc.
16.11. Thermo Fisher Scientific Inc.
16.12. Lucence Diagnostics Pte Ltd.
17. Strategic Recommendations
18. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security